This paper explains that COVID‑19 accelerated adoption of connected respiratory devices and that sponsors must choose technologies carefully. It distinguishes active devices that require subject participation from passive, wearable devices; the latter are prized because they provide continuous, high‑quality data with minimal patient burden. The paper reviews technologies such as site spirometry (gold standard but labour‑intensive), peak expiratory flow meters (easy to use but less comprehensive) and home spirometry, which offers comparable data at home. Breath biomarkers like FeNO/eCO and wearable vitals monitors are also highlighted. Sponsors must evaluate devices’ therapeutic alignment, patient burden, vendor management and risk mitigation to ensure trial success.

Join for free to read